HEALTH PROMOTING COMPOSITION AND METHODS OF USE SUPPLEMENT
The present disclosure is directed to a composition or nutritional supplement containing undenatured Type II collagen in combination with a Vitamin B compound or derivative thereof or any agent that can bind and/or activate the GPR109a receptor such as butyrates and dietary fibers and probiotics resulting to an increase in butyrates. The different dietary or nutraceutical agents are capable of synergistically working together to improve the health and well-being of a human or animal. For instance, the nutritional supplement can be used to treat joint discomfort and pain, improve immune, gastrointestinal and brain health, lowering cholesterol, or otherwise reducing inflammation in human and animal populations both at risk and actively presenting with such ailments.
1 . A composition comprising:
a Type II collagen source combined with a Vitamin B compound, or derivative, or precursor thereof or a GPR109a receptor ligand.
2 . A composition as defined in claim 1 , wherein the composition comprises a nutritional supplement for taking orally.
3 . A composition as defined in claim 1 , wherein the composition comprises a topical composition for applying to skin.
4 . A composition as defined in claim 1 , wherein the Type II collagen source comprises an undenatured Type II collagen.
5 . A composition as defined in claim 2 , wherein the nutritional supplement is in the form of individual dosage vessels.
6 . A composition as defined in claim 5 , wherein the dosage vessels comprise tablets, capsules, gummy chewables, edible films, liquid suspensions, powders, syrups, or lozenges.
7 . A composition as defined in claim 1 , wherein the Vitamin B compound or derivative or precursor thereof or GPR109a receptor ligand comprises a nicotinate.
8 . A composition as defined in claim 1 , wherein the Vitamin B compound or derivative or precursor thereof or GPR109a receptor ligand comprises niacin.
9 . A composition as defined in claim 1 , wherein the Vitamin B compound or derivative or precursor thereof or GPR109a receptor ligand comprises niacinamide.
10 . A composition as defined in claim 1 , wherein the Vitamin B compound, or derivative, or precursor thereof or GPR109a receptor ligand comprises tryptophan.
11 . A composition as defined in claim 1 , wherein the Vitamin B compound or derivative or precursor thereof or GPR109a receptor ligand comprises nicotinamide dinucleotide.
12 . A composition as defined in claim 1 , wherein the Vitamin B compound or derivative, or precursor thereof or GPR109a receptor ligand comprises a niacinamide N-oxide, a salt of niacinamide, nicotinamide adenine dinucleotide phosphate, a tryptophan dipeptide, a nicotinyl alcohol, a nicotinic acid ester, a nicotinyl amino acid, a nicotinyl alcohol ester, or mixtures thereof.
13 . A composition as defined in claim 5 , wherein the individual dosage vessels contain from about 1 mg to about 15,000 mg of the Type II collagen.
14 . A composition as defined in claim 5 , wherein the individual dosage vessels contain from about 0.1 milligrams to about 10,000 milligrams of the Vitamin B compound or derivative, or precursor thereof or GPR109a receptor ligand.
15 . A composition as defined in claim 13 , wherein the Vitamin B compound or derivative or precursor thereof or GPR109a receptor ligand comprises niacin or nicotinamide dinucleotide and wherein the niacin or nicotinamide dinucleotide are present in each dosage vessel in an amount from about 0.1 milligrams to about 200 milligrams.
16 . A composition as defined in claim 13 , wherein the Vitamin B compound or derivative, or precursor thereof or GPR109a receptor ligand comprises niacinamide or tryptophan and the niacinamide or tryptophan are present in each dosage vessel in an amount from about 10 milligrams to about 8,000 milligrams.
17 . A composition as defined in claim 1 , wherein the Vitamin B compound or derivative, or precursor thereof or GPR109a receptor ligand comprises the GPR109a receptor ligand.
18 . A composition as defined in claim 17 , wherein the GPR109a receptor ligand comprises a fatty acid or salt thereof.
19 . A composition as defined in claim 17 , wherein the GPR109a receptor ligand comprises butyric acid or a butyrate.
20 . A composition as defined in claim 17 , wherein the GPR109a receptor ligand is derived from probiotic or dietary fiber metabolism.
21 . A method of treating joint pain in a mammal comprising administering a composition to the mammal comprising a Type II collagen combined with a Vitamin B compound or derivative, or precursor thereof, the composition being administered to the mammal in a therapeutically effective amount sufficient to reduce joint pain in both healthy individuals and individuals with arthritis.
22 . A method for reducing inflammation, improving immune system health, improving gastrointestinal health, improving brain health and/or lowering cholesterol in a mammal comprising administering to the mammal a composition comprising a Type II collagen source combined with a Vitamin B compound or derivative, or precursor thereof, the composition being administered to the mammal in a therapeutically effective amount sufficient to reduce inflammation, improve immune system, gastrointestinal and brain health, and/or lower cholesterol.